Prestige Consumer Healthcare Inc.

PBH's RSI of 30.3 signals deeply oversold conditions, yet the stock trades at a modest P/E of 13.3—substantially cheaper than most pharma peers. With a $2.5B market cap and only 6.87% short interest, there's limited squeeze potential, but the combination of depressed momentum and reasonable valuation creates an interesting asymmetry. The stock's distance from its 52-week high suggests it has already absorbed meaningful selling pressure. Whether this represents capitulation or a warning signal depends on underlying business fundamentals, but the oversold technical setup against historically modest multiples leaves room for mean reversion if sentiment shifts.